)
Overview
<ul>
<li>US respiratory device maker’s Q1 revenue grew 3.4% yr/yr, driven by international demand</li>
<li>Company authorized $30 mln share repurchase program</li>
<li>Inogen reiterated full-year 2026 revenue guidance</li>
</ul>
Outlook
<ul>
<li>Inogen expects Q2 2026 revenue between $94 mln and $97 mln</li>
<li>Company reiterates full-year 2026 revenue outlook of $366 mln to $373 mln</li>
<li>Inogen remains committed to driving positive adjusted EBITDA improvement in 2026</li>
</ul>
Result Drivers
<ul>
<li>INTERNATIONAL SALES - Higher demand for portable oxygen concentrators in international markets and favorable foreign exchange rates offset lower U.S. sales and rentals</li>
<li>COST IMPROVEMENTS - Adjusted gross margin rose due to cost improvements in total cost of revenue</li>
<li>R&amp;D INVESTMENT - Increased research and development spending contributed to a negative adjusted EBITDA Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q1 Beat $85.10 $82.35
Revenue mln mln (2
Analysts
)
Q1 Beat -$4 mln -$7.70
Adjusted mln (2
Net Analysts
Income )
Q1 Net -$8.30
Income mln
Q1 Miss -$1.40 -$1.35
Adjusted mln mln (2
EBITDA Analysts
)
Q1 Gross 44.50%
Margin
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Inogen Inc is $12.00, about 68.8% above its May 6 closing price of $7.11 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

INGN

Reuters

Inogen Q1 revenue rises on international demand